

Dinutuximab

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Dinutuximab

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Central Nervous System Malignancies

Therapeutic Indication: <32 years old with high-risk neuroblastoma after remission and stem cell transplantation

Experimental Arm: Dinutuximab + Cis retinoic acid+GMCSF+IL2

Control Arm: Cis retinoic acid

